COVID-19 Information: VUMC COVID-19 Information | VUMC Patients and Visitors | Specific Diseases and Conditions | 3rd-Dose FAQ

Partners in Discovery

Vanderbilt-Ingram Cancer Center

Vanderbilt-Ingram Cancer Center is at the forefront of new discoveries that help us prevent, find, treat, manage and cure cancer. But we can't make these discoveries alone. Our patients, caregivers, community leaders, donors, volunteers, and educators contribute their insight, time, and passion to advancing the discoveries that lead us closer to a cure.

No matter how cancer has touched your life, you are a key partner in our efforts to save lives and improve the quality of life for those with cancer.

_{Harnessing the power of

science for our patients}

_{Our doctors and researchers are turning today's}
_{scientific discoveries into tomorrow's treatments.}
_{Learn more about our research programs and initiatives.}

Research Programs

Specialized Programs of Research Excellence (SPOREs)

Research Centers & Initiatives

Proven Track Record

A leader in research, innovation and treatment. We are one of 51 National Cancer Institute-designated Comprehensive Cancer Centers, dedicated to an integrated and patient-focused approach.

Patients, Partners, Progress

Our patients and families are our most important partners in discovery – and the motivation behind our efforts to advance research and improve cancer care.

Read their stories from Momentum magazine.

We’ve Only Just Begun

Facing cancer with youthful resilience

Pay it Forward

Bladder cancer research fund honors mentor

Blazing a new trail

Clinical trial participant forges a different treatment path

Berlin named interim leader of Hematology and Oncology

Jordan Berlin, MD, has been appointed interim leader of the Division of Hematology and Oncology.

VUMC’s Pietenpol, Shyr named AACR Fellows

The AACR has inducted Jennifer Pietenpol, PhD, and Yu Shyr, PhD, into the 2022 class of Fellows of the AACR Academy.

Ferrell lands Mark Foundation for Cancer Research award

The Mark Foundation for Cancer Research has selected four outstanding scientific research projects to receive funding for its 2022 Endeavor Awards.

Study finds World Trade Center responders at higher risk for blood cancer-associated mutations

Scientists VICC collaborated with researchers from New York to determine that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease.

Park named director of Vanderbilt-Ingram Cancer Center

Ben Ho Park, MD, PhD, Cornelius Abernathy Craig Professor of Medicine, and deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director.

Pietenpol named chief scientific and strategy officer

Jennifer Pietenpol, PhD, is stepping down from her long-held role as the Cancer Center’s director to focus on a combined leadership role for VUMC as chief scientific and strategy officer.